PCV70 - EFFECT OF TIME IN THERAPEUTIC RANGE ON COST AND CLINICAL OUTCOMES OF ATRIAL FIBRILATION PATIENTS - A COST-CONSEQUENCES ANALYSIS OF RIVAROXABAN VS WARFARIN FOR TURKEY
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.617
https://www.valueinhealthjournal.com/article/S1098-3015(18)33917-2/fulltext
Title :
PCV70 - EFFECT OF TIME IN THERAPEUTIC RANGE ON COST AND CLINICAL OUTCOMES OF ATRIAL FIBRILATION PATIENTS - A COST-CONSEQUENCES ANALYSIS OF RIVAROXABAN VS WARFARIN FOR TURKEY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33917-2&doi=10.1016/j.jval.2018.09.617
First page :
Section Title :
Open access? :
No
Section Order :
33